Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001663364 | SCV001873657 | uncertain significance | not provided | 2024-10-07 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV002539595 | SCV003722462 | uncertain significance | Inborn genetic diseases | 2022-02-02 | criteria provided, single submitter | clinical testing | The c.1562C>T (p.P521L) alteration is located in exon 2 (coding exon 1) of the MYO15A gene. This alteration results from a C to T substitution at nucleotide position 1562, causing the proline (P) at amino acid position 521 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV001663364 | SCV004325454 | benign | not provided | 2024-01-11 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001663364 | SCV005192765 | uncertain significance | not provided | criteria provided, single submitter | not provided |